All In Biotech

NDA 009830 · Bausch

Mestinon

Pyridostigmine Bromide · Injection

Last checked: Nov 20, 2026Latest source record: Jul 26, 2001 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1955

Oct 2, 1955

Approved uses

1

Original approval plus efficacy supplements

Registered trials

45

6 Phase 3, 6 recruiting

FAERS reports

7,620

5,403 serious, 526 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 1955 Original approval · Type 3 - New Dosage Form
1 products under this application
  • MESTINON · PYRIDOSTIGMINE BROMIDE 5MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pyridostigmine" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myasthenia gravis878
  • fatigue781
  • drug ineffective635
  • asthenia614
  • off label use598
  • diarrhoea565
  • headache537
  • dyspnoea527
  • nausea480
  • muscular weakness410
  • fall389
  • dizziness344

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200565
200679
200778
2008109
2009114
201099
2011138
2012145
2013121
2014120
2015221
2016325
2017311
2018377
2019499
2020548
2021438
2022448
2023718
2024903
2025951
2026751

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mestinon (Pyridostigmine Bromide)

2024 spending

$7.8M

Beneficiaries

450

2,025 claims

Per beneficiary

$17,243

$25.73 per unit

View as table
YearSpending
2020$8,353,546
2021$7,349,795
2022$7,570,178
2023$7,488,212
2024$7,759,474

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 234 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.